Nucleome Therapeutics Introduces First Development Candidate to Combat Chronic Inflammatory Diseases Nucleome Therapeutics takes a major step in treating chronic inflammatory diseases with the nomination of its first preclinical development candidate, NTP464, leveraging cutting-edge technology and insights.

Nucleome Therapeutics Introduces First Development Candidate to Combat Chronic Inflammatory Diseases #United_Kingdom #Oxford #Chronic_Inflammation #Nucleome_Therapeutics #NTP464